Snapshot · Abbott Laboratories (ABT)

Data as of 2026-09-01T22:37:43.840Z

Fundamentals check

Market cap

$188.6B

P/E (TTM)

35.0

Gross margin

56.8%

Net margin

11.6%

ROE

10.5%

R&D / revenue

6.8%

Dividend yield

2.3%

FCF yield

4.6%

Latest dividend: $0.63/share (ex-date 2026-07-15, quarterly)

Summary

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

How it makes money

Revenue mix, latest fiscal year

• Medical Devices48.3%
• Diagnostic Products20.2%
• Nutritional Products19.1%
• Established Pharmaceutical Products12.5%

Recent Events

• 2026-08-31T08:00:00.000Zneutral

  Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula

  这则产品发布事件可能与 Abbott 的市场定位相关，恰逢市场对新生儿配方奶的关注增长，但尚未证明对股价因果。

  Source: prnewswire.com

• 2026-08-31T04:16:19.000Zneutral

  Callan Family Office LLC Invests $8.55 Million in Abbott Laboratories $ABT

  大额机构投资动向或与持股结构变化相关，可能与投资者情绪变化有关，但不直接等同于股价因果。

  Source: defenseworld.net

• 2026-08-27T21:50:02.000Znegative

  Abbott (ABT) Stock Sinks As Market Gains: Here's Why

  股价走低的报道可能与市场环境相关，尚不能确认因果，或有助于理解市场对 Abbott 的情绪。

  Source: Zacks Investment Research

• 2026-08-27T09:00:00.000Zneutral

  Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke

  CE Mark 可能与 Abbott 的技术领导力相关，恰逢监管批准事件，但不直接证明股价走向。

  Source: prnewswire.com

• 2026-07-16T00:00:00.000Zpositive

  Price move: ABT rose 10.7%

  ABT 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-07-02T00:00:00.000Zpositive

  Price move: ABT rose 3.5%

  ABT 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-23T00:00:00.000Zpositive

  Price move: ABT rose 3.1%

  ABT 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-06-04T00:00:00.000Zpositive

  Price move: ABT rose 4.4%

  ABT 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $122.86 from 7 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-25SellFord Robert B(director, officer: CHAIRMAN AND CEO)180,297 shares
• 2026-08-25SellFord Robert B(director, officer: CHAIRMAN AND CEO)218,535 shares
• 2026-08-11SellMorrone Louis H.(officer: EXECUTIVE VICE PRESIDENT)5,850 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。